These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 17976922)

  • 21. Antidepressant-like effects of the cannabinoid receptor ligands in the forced swimming test in mice: mechanism of action and possible interactions with cholinergic system.
    Kruk-Slomka M; Michalak A; Biala G
    Behav Brain Res; 2015 May; 284():24-36. PubMed ID: 25660201
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The selective glucocorticoid receptor antagonist CORT 108297 decreases neuroendocrine stress responses and immobility in the forced swim test.
    Solomon MB; Wulsin AC; Rice T; Wick D; Myers B; McKlveen J; Flak JN; Ulrich-Lai Y; Herman JP
    Horm Behav; 2014 Apr; 65(4):363-71. PubMed ID: 24530653
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cannabinoid type 1 receptor blockade promotes mitochondrial biogenesis through endothelial nitric oxide synthase expression in white adipocytes.
    Tedesco L; Valerio A; Cervino C; Cardile A; Pagano C; Vettor R; Pasquali R; Carruba MO; Marsicano G; Lutz B; Pagotto U; Nisoli E
    Diabetes; 2008 Aug; 57(8):2028-36. PubMed ID: 18477809
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inducible cAMP early repressor regulates corticosterone suppression after tricyclic antidepressant treatment.
    Conti AC; Kuo YC; Valentino RJ; Blendy JA
    J Neurosci; 2004 Feb; 24(8):1967-75. PubMed ID: 14985439
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential effects of imipramine and CORT118335 (Glucocorticoid receptor modulator/mineralocorticoid receptor antagonist) on brain-endocrine stress responses and depression-like behavior in female rats.
    Nguyen ET; Caldwell JL; Streicher J; Ghisays V; Balmer NJ; Estrada CM; Solomon MB
    Behav Brain Res; 2018 Jan; 336():99-110. PubMed ID: 28866130
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of the CB
    Poleszak E; Wośko S; Sławińska K; Wyska E; Szopa A; Świąder K; Wróbel A; Doboszewska U; Wlaź P; Wlaź A; Serefko A
    Pharmacol Biochem Behav; 2020 Jan; 188():172833. PubMed ID: 31785246
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The temporal dynamics of intrahippocampal corticosterone in response to stress-related stimuli with different emotional and physical load: an in vivo microdialysis study in C57BL/6 and DBA/2 inbred mice.
    Thoeringer CK; Sillaber I; Roedel A; Erhardt A; Mueller MB; Ohl F; Holsboer F; Keck ME
    Psychoneuroendocrinology; 2007 Jul; 32(6):746-57. PubMed ID: 17583438
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CB1 cannabinoid receptors mediate anxiolytic effects: convergent genetic and pharmacological evidence with CB1-specific agents.
    Haller J; Varga B; Ledent C; Freund TF
    Behav Pharmacol; 2004 Jul; 15(4):299-304. PubMed ID: 15252281
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Disruption of peri-adolescent endocannabinoid signaling modulates adult neuroendocrine and behavioral responses to stress in male rats.
    Lee TT; Hill MN; Hillard CJ; Gorzalka BB
    Neuropharmacology; 2015 Dec; 99():89-97. PubMed ID: 26192544
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rimonabant, a potent CB1 cannabinoid receptor antagonist, is a Gα
    Porcu A; Melis M; Turecek R; Ullrich C; Mocci I; Bettler B; Gessa GL; Castelli MP
    Neuropharmacology; 2018 May; 133():107-120. PubMed ID: 29407764
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Involvement of CB
    Sartim AG; Moreira FA; Joca SRL
    Neuroscience; 2017 Jan; 340():126-134. PubMed ID: 27771531
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The CB1 Neutral Antagonist AM4113 Retains the Therapeutic Efficacy of the Inverse Agonist Rimonabant for Nicotine Dependence and Weight Loss with Better Psychiatric Tolerability.
    Gueye AB; Pryslawsky Y; Trigo JM; Poulia N; Delis F; Antoniou K; Loureiro M; Laviolette SR; Vemuri K; Makriyannis A; Le Foll B
    Int J Neuropsychopharmacol; 2016 Dec; 19(12):. PubMed ID: 27493155
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The orexigenic effect of ghrelin is mediated through central activation of the endogenous cannabinoid system.
    Kola B; Farkas I; Christ-Crain M; Wittmann G; Lolli F; Amin F; Harvey-White J; Liposits Z; Kunos G; Grossman AB; Fekete C; Korbonits M
    PLoS One; 2008 Mar; 3(3):e1797. PubMed ID: 18335063
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Forced swim test-induced endocrine and immune changes in the rat: effect of subacute desipramine treatment.
    Connor TJ; Kelly JP; Leonard BE
    Pharmacol Biochem Behav; 1998 Jan; 59(1):171-7. PubMed ID: 9443552
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bladder function in a cannabinoid receptor type 1 knockout mouse.
    Füllhase C; Campeau L; Sibaev A; Storr M; Hennenberg M; Gratzke C; Stief C; Hedlund P; Andersson KE
    BJU Int; 2014 Jan; 113(1):144-51. PubMed ID: 24053792
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of milk ingestion and growth after administration of a neutral cannabinoid CB1 receptor antagonist on the first postnatal day in the mouse.
    Fride E; Braun H; Matan H; Steinberg S; Reggio PH; Seltzman HH
    Pediatr Res; 2007 Nov; 62(5):533-6. PubMed ID: 17805201
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting the Endocannabinoid/CB1 Receptor System For Treating Major Depression Through Antidepressant Activities of Curcumin and Dexanabinol-Loaded Solid Lipid Nanoparticles.
    He X; Yang L; Wang M; Zhuang X; Huang R; Zhu R; Wang S
    Cell Physiol Biochem; 2017; 42(6):2281-2294. PubMed ID: 28848078
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Attenuation of basal and cocaine-enhanced locomotion and nucleus accumbens dopamine in cannabinoid CB1-receptor-knockout mice.
    Li X; Hoffman AF; Peng XQ; Lupica CR; Gardner EL; Xi ZX
    Psychopharmacology (Berl); 2009 May; 204(1):1-11. PubMed ID: 19099297
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The cannabinoid CB1 receptor antagonist rimonabant stimulates 2-deoxyglucose uptake in skeletal muscle cells by regulating the expression of phosphatidylinositol-3-kinase.
    Esposito I; Proto MC; Gazzerro P; Laezza C; Miele C; Alberobello AT; D'Esposito V; Beguinot F; Formisano P; Bifulco M
    Mol Pharmacol; 2008 Dec; 74(6):1678-86. PubMed ID: 18801918
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CB1 receptor blockade reduces the anxiogenic-like response and ameliorates the neurochemical imbalances associated with alcohol withdrawal in rats.
    Rubio M; Fernández-Ruiz J; de Miguel R; Maestro B; Michael Walker J; Ramos JA
    Neuropharmacology; 2008 May; 54(6):976-88. PubMed ID: 18371990
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.